Next-Generation Sequencing: Scientific and Commercial Implications of the $1000 Genome

By Kevin Davies, PhD

SECTION 1
A BRIEF HISTORY OF GENOME SEQUENCING TECHNOLOGY AND MILESTONES
      Dideoxy (Sanger) Sequencing
      Automated DNA Sequencing
      Genome Wars
      The $1,000 Genome

SECTION 2
BEYOND SANGER SEQUENCING: NEXT-GENERATION SEQUENCING TECHNOLOGIES
      Sequencing-by-Synthesis/Pyrosequencing
      Sequencing-by-Synthesis
            Illumina
            GE Healthcare
            Intelligent Bio-Systems
      SOLiD (Supported Oligonucleotide Detection)
            Storage
      Polony Sequencing
      Single-Molecule Sequencing
            VisiGen
            Pacific Biosciences
      Nanopore Sequencing
      Optical Trapping
      Nanoscale Sanger Sequencing

SECTION 3
APPLICATIONS OF NEXT-GENERATION SEQUENCING
      The $1,000 Genome/Personal Genomics
      The Cancer Genome Atlas
      Evolutionary Genomics
      Environmental Genomics
      Gene Regulation

SECTION 4
EXPERT INTERVIEWS WITH TECHNOLOGY INNOVATORS
      Tony Smith, PhD, Illumina
      Susan Hardin, PhD, VisiGen
      Jay Shendure, MD, PhD, University of Washington, Seattle
      Kevin McKernan, ABI
      Stanley N. Lapidus, Helicos

SECTION 5
NEXT-GENERATION COMPANIES
      Applied Biosystems
      GE Healthcare
      Helicos BioSciences
      Illumina/Solexa
      Intelligent Bio-Systems
      Pacific Biosciences
      Reveo
      Roche/454 Life Sciences
      VisiGen

SECTION 6
CHI INSIGHT PHARMA REPORTS—NEXT-GENERATION SEQUENCING SURVEY—FEBRUARY 2007

APPENDIX
NHGRI RESEARCH GRANTS
      $1,000 Genome Grants (August 2005)
      $100,000 Genome Grants

References

Company Index with Web Addresses